Long-term follow-up of the west of scotland coronary prevention study [1]

New England Journal of Medicine

Volumn 358, Issue 2, 2008, Pages 193-195

  McEvoy, John W ^a   Margey, Ronan ^a   Blake, Gavin J ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CONTROL; DISEASE COURSE; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; INCIDENCE; NOTE; CHEMICALLY INDUCED DISORDER; HYPERCHOLESTEROLEMIA; LYMPHOMA; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER RISK; MORBIDITY;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; DIABETES MELLITUS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PRAVASTATIN; HYPERCHOLESTEROLEMIA; LYMPHOMA;

EID: 38049158275     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc076463     Document Type: Article

References (2)

1. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86.
2. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.